Physician profile
Katy Mclaughlin
NPI 1255789772
$6,596.23
in general payments reported to CMS, 2019-2025
27 companies · $2,093 in 2025
The $2,093 reported for 2025 was more than what 90% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $551 · 2022: $1,297 · 2023: $1,208 · 2024: $1,446 · 2025: $2,093.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,748.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,747.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,910.78 | 2021-2025 | |
| Tris Pharma INC | $702.64 | 2022-2025 | Dyanavel Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $535.43 | 2021-2025 | Trintellix |
| Vanda Pharmaceuticals INC. | $492.99 | 2021-2025 | Fanapt, Hetlioz |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $456.46 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $359.70 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $320.69 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Neurocrine Biosciences, INC. | $235.71 | 2022-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $201.00 | 2021-2025 | Austedo Xr, Uzedy |
| Idorsia Pharmaceuticals US INC | $189.53 | 2023-2024 | Quviviq |
| Supernus Pharmaceuticals, INC. | $188.57 | 2024-2025 | Qelbree |
| Bausch Health US, LLC | $148.34 | 2025 | Aplenzin |
| Lundbeck LLC | $115.76 | 2022-2025 | Rexulti |
| Sunovion Pharmaceuticals INC. | $109.84 | 2022 | |
| Corium, LLC | $95.75 | 2025 | Azstarys |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $80.80 | 2022 | |
| Axsome Therapeutics, INC. | $80.00 | 2025 | Auvelity |
| Biogen, INC. | $66.36 | 2023 | |
| Noven Therapeutics, LLC | $60.99 | 2024 | Xelstrym |
| Almatica Pharma LLC | $60.32 | 2022 | |
| Janssen Pharmaceuticals, INC | $53.51 | 2022-2025 | Spravato |
| Eisai INC. | $34.34 | 2021 | |
| Tempus Ai, INC | $29.80 | 2025 | Xt Cdx |
| E.R. Squibb & Sons, L.L.C. | $19.76 | 2025 | Cobenfy |
| Collegium Pharmaceutical, INC. | $17.07 | 2025 | Jornay Pm |
| Sage Therapeutics, LLC | $16.48 | 2025 | Zurzuvae |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.61 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katy Mclaughlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.